Therapeutic Expertise

Revolutionizing central nervous system research with cutting-edge lab testing solutions

Our team offers expert biomarker assessments designed to help accelerate clinical breakthroughs.

Home / Therapeutic Expertise / Central Nervous System

ON-DEMAND WEBINAR

Decoding Alzheimer’s: Trial designs, biomarker breakthroughs and redefining patient-first strategies

Join experts from across IQVIA as they share the latest advances in Alzheimer’s disease (AD) clinical research. From breakthrough biomarkers for early patient identification to leveraging global site networks, our leaders will discuss actionable strategies for optimizing Alzheimer’s clinical trials.

Listen Now

IQVIA Laboratories delivers globally harmonized lab testing solutions across Phase 1, 2, and 3 clinical studies, supporting biomarker testing for disease identification, inflammation analysis, and various intended-use applications.

Our expansive network of CAP CLIA-certified laboratories ensures seamless integration into clinical development programs, offering a broad range of tailored services.

Discovery & Translational Science Assay Development

Driving innovation by developing novel assays across diverse matrices such as blood, serum/plasma, and cerebrospinal fluid.

Global Testing Capabilities

Providing harmonized testing solutions across the US, EU, China, and Singapore, powered by advanced instrumentation including Roche Elecsys, Lumipulse, Quanterix Simoa, MSD, Luminex, and more.

Regulatory-Compliant Testing

Meeting global regulatory requirements with precise, intended use testing solutions designed to support clinical advancements.

Luminex^® Multi-Analyte Profiling (MAP)

Enabling multiplex biomarker analysis with unparalleled precision.

Quanterix™ Single-Molecule Array (Simoa^®)

Delivering ultrasensitive immunoassay detection for enhanced data accuracy.

Olink^®Proximity Extension Assay (PEA)

Olink Certified Service Provider

TruCulture Ex Vivo Immune Monitoring System

Providing a closed system for whole blood collection and culturing at the collection site.

Lumipulse
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test supports discovery and translational science services for various clinical applications.

Roche Elecsys
Elecsys® pTau181 blood test helps rule out amyloid pathology, streamlining Alzheimer's diagnosis.

Mesoscale
Meso Scale Discovery (MSD).

100 studies

Alzheimers Disease

25 Phase I
25 Phase II
50 phase III/IV

70 studies

Parkinsons Disease

25 phase I
20 phase II
25 phase III/IV

90 Studies

Schizophrenia

45 phase I
10 phase II
35 phase III/IV

30 Studies

ALS

19 phase I
4 phase II
7 phase III/IV

110 Studies

Other areas

Alzheimer's: 100 studies

25 phase I
25 phase II
50 phase III/IV

Parkinson's: 70 studies

25 phase I
20 phase II
25 phase III/IV

Schizophrenia: 90 studies

45 phase I
10 phase II
35 phase III/IV

ALS: 30 studies

19 phase I
4 phase II
7 phase III/IV

Alzheimer’s Disease Clinical Trials

Over 55 million people worldwide were suffering of dementia in 2020. This number is expected to almost double every 20 years, reaching 78 million in 2030 and rising to 139 million in 2050. The worldwide cost of dementia is estimated at US$1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030.

Download Our Insight Brief

226_Female doctor examining brain scan on tablet

Robust Global Test Menu

IQVIA Laboratories offers harmonized lab testing across Phase I–III clinical studies. With our expansive network of CAP- and CLIA-certified laboratories, we deliver biomarker testing solutions that accelerate disease identification, inflammation analysis, and intended-use applications.

View Test Menu